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Abstract: Endogenous gas transmitters, hydrogen sulfide (H2S), carbon monoxide (CO) and nitric 
oxide (NO) are important signaling molecules known to exert multiple biological functions. In recent 
years, the role of H2S, CO and NO in regulation of cardiovascular, neuronal and digestive systems 
physiology and pathophysiology has been emphasized. Possible link between these gaseous mediators 
and multiple diseases as well as potential therapeutic applications has attracted great attention from 
biomedical scientists working in many fields of biomedicine. Thus, various pharmacological tools 
with ability to release CO or H2S were developed and implemented in experimental animal in vivo 
and in vitro models of many disorders and preliminary human studies. This review was designed to 
review signaling functions, similarities, dissimilarities and a possible cross-talk between H2S and CO 
produced endogenously or released from chemical donors, with special emphasis on gastrointestinal 
digestive system pathologies prevention and treatment.
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1. Introduction
Hydrogen sulfide (H2S) and carbon monoxide (CO), next to nitric oxide (NO) are the most recently 
studied endogenous gaseous mediators. Chemically, exogenous CO is a colorless and odorless gas 
lighter than air, while colorless H2S has characteristic smell of rotten eggs. Both gaseous molecules 
were assumed for many years to be toxic for human body and when generated in the mammalian 
tissues, they were considered only as a by-product of metabolic processes or, as in case of H2S, 
as the end product of anaerobic respiration due to bacteria capable of utilizing inorganic sulfur 
substrates [1,2]. However, based on scientific evidence, the second beneficial face of CO and H2S 
has been reported recently. It has been shown that these gaseous mediators, similarly to NO, play 
an important beneficial functions in the body among others including the regulation of homeostasis, 
vasorelaxation, the regulation of various enzymes activity and the modulation of the particular genes 
expression [1- 4]. These small gaseous molecules have become the main target of many investigations 
in the context of various diseases including gastrointestinal (GI) pathologies. However, due to toxicity 
of inhaled CO or H2S, novel compounds were designed and developed with ability to release small 
amounts of these gaseous molecules and are widely used as pharmacological tools under experimental 
conditions [5]. Interestingly, it seems that together with NO, all three mediators form a kind of 
endogenous triad interacting with each other [6]. However, these aspects have not been investigated 
deeply so far. Thus, within this article we aimed to explain and highlight possible mechanisms of
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interaction and the cross-talk between CO and H2S biosynthesis pathways, with special emphasis on 
the development, prevention and treatment of gastrointestinal (GI) and digestive system pathologies.
2. Overview on CO and H2S Physiology and Pharmacology in Digestive System
2.1. H2S Physiology and Pharmacology
H2S is known to modulate various biological functions on molecular, biochemical and even 
functional level under physiological and pathological conditions. This molecule can be formed 
in both, enzymatic and non-enzymatic processes. Three enzymes are involved in the enzymatic 
production of H2S in the body: cystathionine-y-lyase (CTH), cystathionine p-synthase (CBS) and 
3-mercaptopyruvate sulfurtransferase (MPST) [7]. CTH and CBS are located in cytosol and their 
activity requires pyridoxal-5'-phosphate (P5P; vitamin B6) as a cofactor. MPST is present within cytosol 
and mitochondria and is P5P-independent but works in co-activity with cysteine aminotransferase 
(CAT), which is necessary to convert cysteine to 3-mercaptopyruvate, a substrate for MPST [7]. 
As mentioned before, the colonic sulfate-reducing bacteria could be also the source of H2S in the GI 
tract [8]. The molecular targets of endogenous H2S include many physiologically important proteins, 
signaling targets including kinases, phosphatases, thiols, polysulfide's, thiosulfate/sulfite, iron-sulfur 
cluster proteins, the anti-oxidant compounds and transcriptional factors affecting multiple cellular 
and molecular responses. Thus, this mediator is involved in the regulation of signaling pathways and 
genes expression [9].
Numerous studies have shown that H2S has anti-oxidative, anti-inflammatory and cytoprotective 
properties [5,10]. The anti-inflammatory effect of H2S is assumed to result in inhibition of endothelial 
leukocyte adhesion, modulation of inflammatory markers expression, prostaglandins biosynthesis and 
by interacting with transcription factors such as nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-kB) and nuclear factor erythroid 2-related factor 2 (Nrf-2) [10,11]. NF-kB regulates the 
expression of genes encoding pro-inflammatory cytokines, some growth factors, cyclooxygenase-2 
(COX-2) and apoptotic pathways components [12]. Its activation has been noted in various inflammatory 
diseases, such as rheumatoid arthritis, multiple sclerosis, atherosclerosis, systemic lupus erythematosus, 
type I diabetes, chronic obstructive pulmonary disease and asthma, and especially in digestive system 
pathologies, including e.g., inflammatory bowel disease (IBD mainly consisting of Crohn's disease 
and ulcerative colitis) and drugs-induced gastrotoxicity [13- 15]. NF-kB inhibition by H2S can occur in 
two possible ways, by sulfhydration of the free thiol group on 38 cysteine in the subunit 65 or due to 
phosphorylation suppression and degradation of IkBa [16,17]. As it has been mentioned above, H2S can 
also interact with another transcription factor, Nrf-2, which regulates cellular defensive response to 
inflammation and oxidation [11,18]. Physiologically, Nfr-2 is present in the cytoplasm as a molecular 
complex with the cytoskeleton protein, Keap1. When cellular redox homeostasis is imbalanced, Nrf-2 
is released from its repressor (Keap1), translocated to the nucleus and bound to promoter of antioxidant 
responsive element (ARE). This translocation leads to increased transcription for anti-oxidative genes, 
such as catalase (CAT) or superoxide dismutase (SOD) [19,20], glutathione-S-transferase (GST) and 
glutathione peroxidase (GPx) [11,18]. H2S most likely activates Nrf-2 pathway by sulfuration the 
Keap1 protein (at the cysteine-151, 226 and 613), leading to this nuclear factor release, its nuclear 
translocation and enhancement of antioxidant genes expression [18]. H2S is also supposed to exert 
its anti-inflammatory activity due to the modulation of annexin A1 (AnxA1) pathway. H2S triggers 
AnxA1 mobilization and modulates vascular inflammatory processes by the enhancement in the 
detachment rate of leukocytes from the vessel wall resulting in reduction of inflammation [21]. 
This gaseous molecule can interact with the endogenous NO in vasomotor responses of the arterial 
vessels involved in the blood pressure control. Previous study concerning the systolic blood pressure 
(sBP), vasoreactivity, NO-synthase (NOS) expression and activity, CTH expression and geometry of the 
isolated thoracic aorta revealed that this vasomotor interaction between H2S released from Na2S with
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NO in thoracic aorta of normotensive and spontaneously hypertensive rats (SHRs) seems to be age- 
and blood pressure-dependent [4].
It has been reported that H2S biosynthesis pathway activity could be crucial for gastric mucosal 
barrier physiology and alterations in this gaseous molecule signaling were observed in pathology 
of upper GI-tract and other parts of the digestive system [5]. Moreover, H2S-releasing NaHS has 
been shown to accelerate ulcer healing and to attenuate non-steroidal anti-inflammatory drugs 
(NSAIDs)-induced gastrotoxicity [22,23]. Interestingly, H2S-releasing derivative of naproxen (ATB-346) 
which successfully completed phase 2 clinical trial, offers a promising safer alternative for conventional 
native form of this NSAID not only in improvement of pain relief but also in GI-safety manifested by 
the reduction of upper GI tract damage formation in subjects treated with equimolar effective doses of 
ATB-346 versus naproxen [24]. Similarly GYY4137, slow H2S-releasing compound has been shown 
to exert anti-inflammatory activity [25] and to decrease the area of ischemia/reperfusion-induced 
gastric damage in rats [23]. GYY4137 also attenuated intestinal barrier injury in mouse model as 
well as in human colon cancer cells model of lipopolysaccharide (LPS) or TNF-a/IFN-y-induced 
endotoxemia [26].
It is also worth mentioning that natural sources of sulfur compounds, such as garlic-derived 
compounds including diallyl sulfide (DAS) disulfide, diallyl disulfide (DADS), diallyl trisulfide 
(DATS) and allicin were described as H2S releasing molecules [27]. Numerous studies have shown 
beneficial therapeutic and protective effects of these compounds in cancer development [24- 26]. 
Cell cultures and animal models, as well as epidemiology data have revealed the chemopreventive 
activity of these H2S donors, especially in gastric and colorectal cancers [28- 30]. On the other hand, 
somehow related to H2S and sulfide physiology, sulfiredoxin (Srx) is multifunction enzyme involved 
in antioxidant metabolism by reduction of cysteine sulfinic acid to sulfenic acid in proteins exposed 
to oxidative stress [31]. Some studies suggested that increased Srx expression could be linked with 
carcinogenesis and tumor progression [29,31]. Indeed, in gastric tumors cells, expression of Srx was 
significantly elevated as compared with normal tissue [29]. Interestingly, it has been reported that 
treatment with DATS decreased expression of Srx in gastric tumor cell line BGC823 [29]. Similarly, 
Srx is highly expressed in poorly differentiated, aggressive HCT116 human colorectal cancer cells, 
while in normal colon epithelium (NCM460) or cells derived from well-differentiated colorectal 
carcinomas (SW640 and HT29) this protein was not detected [32]. It has been also observed that 
inhibition of Srx resulted in selective death of cancer cells by disturbance in redox homeostasis [33]. 
Taken together, we assume that inhibition of Srx could be considered as a novel approach and target 
for anticancer treatment. On the other hand, some studies showed pro-cancer effects of H2S [34- 36]. 
This phenomenon may be associated with induction of angiogenesis, regulation of mitochondrial 
bioenergetics, acceleration of cell cycle progression, and anti-apoptotic actions [34]. It has been reported 
that in adenocarcinoma-derived cell lines (HCT-116, HT-29, LoVo) CBS expression was upregulated as 
compared to control-non-malignant colonic epithelial cells [35]. Moreover, anti-apoptotic effect of H2S 
and its involvement in the enhancement of cell proliferation linked with alterations in CTH expression 
was demonstrated on human gastric adenocarcinoma (AGS) [36]. Taken together, H2S has been shown 
to exert both pro- and anti-cancer effects and we assume that this could be dependent on the dose of 
this gaseous mediator and possibly on the differences in sensitivity of various cell types to the impact 
of this molecule.
Garlic-derived H2S-releasing compounds were also shown to exhibit hepatoprotective effect in 
experimental animal models [37,38]. Pretreatment with DAS decreased NF-kB and TNF-a in serum and 
reversed the decreased level of superoxide dismutase (SOD) and catalase activity in liver as observed 
in a well described model of liver injury induced by carbon tetrachloride (CCl4) [38]. Therefore, 
garlic-derived H2S donors might affect cell signaling networks in a similar way as synthetic H2S donors.
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2.2. CO Physiology and Pharmacology
CO is produced in mammalian tissues by heme degradation involving enzymatic activity of heme 
oxygenases (HMOXs) [2]. This protein has two main isoforms, HMOX-1 and HMOX-2 translated 
by the expression of two separate genes. HMOX-1 is inducible and this isoform is active under 
imbalanced homeostasis conditions, while HMOX-2 is constitutively expressed with relatively low 
yield. Interestingly, rats also encode third isoform, HMOX-3, probably from a pseudogene that 
does not produce a functional form of this protein [39]. It has been indicated that in majority of 
biological systems, CO has been shown to exert anti-inflammatory, anti-proliferative, anti-apoptotic 
and cytoprotective effects, similarly to H2S [39,40]. CO may regulate the activity and functionality of 
various proteins by binding to heme domains. This includes e.g., hemoglobin, myoglobin, cytochrome 
c, cytochrome P450, nitric oxide synthase (NOS), catalase, prostaglandin H synthase, nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase (Nox) and transcription factors NPAS2, Bach-1 and 
Bach-2 [41].
Recently, endogenous CO or that released from the synthetic CO donor, 
tricarbonyldichlororuthenium (II) dimer (CORM-2) has been implicated in the mechanism of 
gastric mucosal integrity, gastroprotection and the healing of chronic gastric ulcers [42,43]. 
These gastroprotective and therapeutic effects of CO are mediated by the activation of soluble 
guanylyl cyclase (sGC), which is regulating cyclic guanosine monophosphate (cGMP) generation. 
Elevated intracellular concentration of this second messenger leads to enhancement in the gastric 
microcirculation as documented by the direct measurement of gastric blood flow (GBF) [40,42,43]. 
Moreover, the potential mediators of this CO-induced beneficial action such as Ca2+-activated K+ 
channels [44] and the arachidonic acid derivative (20-HETE) production, have been proposed to 
mediate vasoactive, gastroprotective and ulcer healing properties of CO [45].
In addition, the anti-apoptotic and anti-hypoxic effects of this gaseous molecule have been 
demonstrated [37]. In animal in vivo and cell culture in vitro models, CO has been shown to 
inhibit LPS-induced overexpression of pro-inflammatory cytokines, such as TNF-a, IL-1p, IL-6, 
macrophage inflammatory protein (MIP)-1 p and granulocyte-macrophage colony-stimulating factor 
(GM-CSF) [44]. It has been assumed that the anti-inflammatory activity of CO is related to the 
possible modulation by this gaseous molecule of the multiple members of the mitogen-activated 
protein kinase (MAPK) family [44]. Fukuda et al. has reported that water-soluble CORM-3 attenuated 
inflammatory response in animal model of trinitrobenzenesulfonic acid (TNBS)-induced colitis by 
targeting CD4+ T cells releasing pro-inflammatory cytokines (e.g., TNF-a, IL-8, INF-y, IL-17A) [46]. 
Interestingly, CO may affect ERK MAPK pathway in T cells inhibiting their proliferation followed 
by the reduced pro-inflammatory cytokines release, as it has been documented in experimental 
mice model of colitis [47]. Moreover, recent evidence has indicated that pretreatment with CORM-3 
alleviated the postoperative ileus (POI) in mice [48]. Similarly to above mentioned observations, 
CORM-3 significantly reduced intestinal inflammation and oxidative stress in postoperative ileus due 
to activation of p38 MAPK and downregulation of ERK1/2 [48]. Taken together, it can be assumed 
that CO has immunomodulatory properties and affects the activity of various cell types including T 
cells, B cells, epithelial cells, neutrophils, mast cells, dendritic cells and macrophages stimulated in the 
course of gastrointestinal digestive disorders [49]. Takagi et al. investigated the effects of CO-releasing 
CORM-A1 on Th17 differentiation using T-cell transfer-induced colitis in mice [50]. They revealed 
that CORM-A1 ameliorated intestinal inflammation through reduction of retinoid related orphan 
receptor (ROR)y-receptor expression, inhibition of Th17 differentiation and by the decrease of IL-17A 
level [50]. HMOX-1/CO pathway can also regulate intestinal inflammation in acute and chronic 
experimental models by cross-talk of this pathway proteins with enteric microbiota in mucosal immune 
compartment [49]. Undoubtedly, CO could be considered as potential therapeutic agent in various GI 
disorders due to the wide range of molecular inflammatory and anti-inflammatory targets affected by 
this small gaseous molecule.
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3. Similarities and Dissimilarities in H2S and CO Activity and their Interaction within 
Digestive System
3.1. Parallelisms and Discrepancies in CO and H2S Effects and Targets
CO and H2S, likewise NO have similar activity and regulate parallel molecular pathways, also due 
to mutual interaction and the cross-talk between these molecules [51,52]. H2S and CO were shown to 
prevent gastric mucosa against NSAIDs- or alendronate-induced damage and to accelerate ulcer healing 
due to an improvement of gastric microcirculation [15,53- 55]. Both molecules attenuated hypoxia 
and inflammation decreasing gastric mucosal expression of HIF-1a and NF-kB [15]. Recent evidence 
indicates that H2S- and CO-gastroprotection was abolished or at least reduced by the inhibition of 
sGC or NOS activity [54,56]. Interestingly, in contrast with H2S, CO was shown to maintain its 
gastroprotective effects independently on afferent sensory nerves activity [56]. On the other hand, 
H2S-releasing NaHS accelerated gastric ulcer healing but in contrast with CO-releasing CORM-2, 
this effect of H2S donor was accompanied by the upregulation of gastric mucosal protein expression 
for Nrf-2, vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFr) at 
the ulcer margin [42,53].
Interestingly, it has been reported that CO donors could exert antibacterial activity against 
Helicobacter pylori (H. pylori) [57]. Nowadays, the gastric colonization with H. pylori constitutes the major 
risk of gastric and duodenal ulcer diseases, mucosa-associated lymphoid tissue (MALT) lymphoma 
and even gastric adenocarcinoma [58]. Antimicrobial action of stimulated murine macrophages was 
enhanced by CORM-2 against H. pylori [57]. Moreover, CORM-2 impaired H. pylori respiration and 
inhibited H. pylori related urease activity [57], however, the role of H2S in H. pylori infection has 
not been fully recognized. On the one hand, H. pylori produces H2S [8], but on the other hand, 
as mentioned above, natural sulfur compounds like garlic have antibacterial activity [59]. Moreover, 
microbiological studies revealed anti-H. pylori potential of DADS derived from garlic powder or garlic 
oil [59]. Antibacterial activity of garlic-derived compounds were shown to be effective in patients 
infected with H. pylori [60]. Furthermore, allicin as an adjuvant to conventional anti-H.pylori therapy 
increased efficiency of H. pylori eradication [61]. However, further studies are required to fully explain 
these bactericidal aspects of H2S donating agents.
Both H2S and CO donors were shown to increase HCO3- secretion in rat duodenum protecting the 
duodenal mucosa against the damage induced by acidic content [62]. Additionally, H2S was observed 
to modulate gastric secretion possibly via activation of TRPV1 channel and the consequent release 
of substance P and in a NF-kB -dependent manner [63]. H2S released from NaHS stimulated the 
secretion of HCO3- in part mediated by the activity of capsaicin-sensitive afferent neurons as well as 
endogenous NO and PGs [64]. Similarly, CORM-2 dose-dependently elevated HCO3- secretion acting 
as the stimulant of endogenous PGs biosynthesis [62].
In another study, de Araujo et al. proposed that adenosine monophosphate-activated protein 
kinase (AMPK) plays an important role as a regulator of cellular energy and metabolism, and could 
be the common target for all above mentioned gaseous mediators [65]. Indeed, AMPK inducers can 
actually exert a beneficial effects within the GI tract, e.g., metformin has been shown to suppress 
esophageal squamous cell carcinoma (ESCC) [66]. Interestingly, the y-subunit of AMPK contains four 
CBS domains located close to the N-terminus of this subunit, operating in pairs known as Bateman's 
domain [67]. The administration of H2S, CO and NO donors increased p-AMPK expression and 
protected gastric mucosa of mice against ethanol-induced lesions [65]. On the other hand, it has been 
also indicated that AMPK stimulates HMOX-1 gene expression within human vascular cells and rat 
arteries via modulation of Nrf2/ARE pathway [6].
Interestingly, H2S donor, DADS has been demonstrated to stabilize hypoxia-inducible factor a  
(HIF-1a) and to prevent colonic mucosa in experimental model of colitis [68]. H2S also is produced by 
intestinal bacteria forming a biofilm lining the mucus surface [69]. Dysbiosis of the gut microbiota 
and "leaky" mucus layer is associated with the pathogenesis of IBD, irritable bowel syndrome
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(IBS), colorectal cancer and extra-intestinal disorders like obesity or metabolic syndrome [70,71]. 
It has been reported that H2S derived from DADS can have additional protective effect on gut 
affecting intestinal microbiota and biofilm formation because treatment with this compound not only 
alleviated intestinal damage but has also effectively reconstituted microbiota biofilm structure in rat 
model of colitis [69,72]. As mentioned before, CO due to its anti-inflammatory activity ameliorated 
intestinal injury in experimental models of colitis by the modulation of pro-inflammatory cytokine 
expression [49]. Experiments carried out in mice showed that enteric microbiota have the ability 
to regulate the activity of intestinal macrophages essential in killing pathogenic bacteria such as 
Salmonella enterica. This bactericidal effect was associated with an induction of HMOX-1/CO pathway 
by microbiota [49,73]. Moreover, the gut microbiota can produce CO due to the presence of enzymes 
with similar functions as HMOX-1. In addition, CO can directly interact with heme-containing groups 
in some intestinal bacteria [73]. Importantly, in patients with ulcerative colitis, increased intestinal 
expression of HMOX-1 has been demonstrated [74]. Thus, the interplay between gasotransmitters and 
gut microbiome may play an important role in maintenance of intestinal homeostasis (Figure 1).
Figure 1. Possible involvement of hydrogen sulfide (H2 S) and carbon monoxide (CO) in physiology of 
intestinal microbiota.
3.2. Cross-talk between CO and H2S Biosynthesis Pathways
3.2.1. Effects of CO on H2S Biosynthesis Pathway
CO has the chemical ability to bind to metal-centered prosthetic groups of many proteins including 
enzymes [75]. Therefore, heme containing proteins could be considered as the main target of molecular 
events associated with CO activity. CBS, similarly to CTH and MPST takes part in endogenous H2S 
production but belongs to the above mentioned type of enzymes. Indeed, it has been reported that 
CO can bind to the prosthetic heme domain of CBS, stabilizing CO-Fe(II)-histidine complex and in 
turn, resulting in this enzyme inhibition [75,76]. CO regulates H2S production, but on the other hand, 
CBS acts in parallel as a CO sensor [75], however, the indirect effect of CO on CTH and MPST activity 
could not be excluded.
With the implementation of metabolomic methods, the decreased activity of CBS, which affected 
remethylation and transsulfuration has been observed (Figure 2). In detail, the CBS inhibition by CO has
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been shown to elevate methionine and S-adenosylmethionine (SAMe) levels resulting in modulation of 
proteins methylation leading to increased generation of anti-oxidants [77,78]. Therefore, CO-mediated 
CBS inhibition is supposed to switch the transsulfuration pathway into the remethylation pathway, 
leading to the wide range of proteins and histones methylation. Indeed, based on in vitro model, 
it has been demonstrated that CO released from CORM-2 enhanced histone H3 protein methylation in 
human monoblastic leukemia U937 cells [79].
Figure 2. Possible impact of carbon monoxide (CO) on cystathionine-(3--synthase (CBS) 
activity resulting in transsulfuration/remethylation switch. Abbreviations: Met: methionine;
SAMe: S-adenosyl-methionine; SAH: S-adenosyl-homocysteine; Hcy: homocysteine; CSE:
cystathionine-y-lyase
Histone modification and DNA methylation work together in mechanism of chromatin 
condensation process which is a morphological hallmark of apoptosis, and its regulatory availability for 
transcription factors. For instance, alterations in DNA methylation have been reported in development 
of both precancerous Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC), despite its 
noticeable role in gastric carcinogenesis [80]. Histological alterations that occur in BE include the 
transformation of normal squamous epithelium into intestinal metaplasia with a further progression 
into dysplasia and finally into adenocarcinoma. Thus, there were also epigenetic alterations observed, 
especially within DNA methylation. Genomic analysis revealed the presence of global hypomethylation 
during the course of metaplasia development [81]. However, the possible involvement of CO and H2S 
in the development of chronic esophageal disorders has not been fully elucidated. Taken together, 
this aspect should be further investigated with the emphasis on possible impact of these gaseous 
mediators in the mechanism of DNA methylation process of these upper GI pathologies.
Interestingly, the interaction of CO with CBS/H2S pathway could be involved in regulation of bile 
secretion since CO attenuated H2S levels, stimulated biliary HCO3- and therefore protected the liver, 
accelerating its detoxification [82]. In fact, H2S may play an essential role in these processes because 
heterozygous knockout (CBS+/-) reversed these effects of CO [82]. However, the inhibition of CTH 
activity by propargylglycine (PAG) induced choleresis in the rat liver suggesting that the increased CO 
and decreased H2S content are responsible for an elevation of bile secretion [83]. Since bile secretion 
strictly depends on the blood flow in mesenteric circulation, the blood vessel vasomotor activity can be 
directly mediated by these endogenous gaseous molecules. Indeed, the anti-contractile effect of H2S 
in both, the rat vascular wall and perivascular tissue has recently been demonstrated using normal 
and SH rats [3,4]. It has been found that pretreatment with PAG elevated the noradrenaline-induced
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contraction in normal but not in spontaneously hypertensive (SH) rats [3]. However, perivascular 
adipose tissue presence increased vasoactive effect of exogenously derived H2S in SH rats [3].
On the other hand, an opposite final effect of CBS inhibition by CO, such as increased H2S 
concentration has been proposed [77]. This could be explained by accumulation of homocysteine 
that compensatively raised CTH activity in endoplasmic reticulum stress model in HEK293 cells, 
an effect also confirmed in CBS deficient mice [84]. This hypothesis could be corroborative with our 
previous finding that pretreatment with CO-donor, CORM-2 not only prevented gastric lesions induced 
by aspirin but also downregulated gastric mucosal protein expression of CBS and subsequent H2S 
production [54]. However, in chronic experimental gastric ulcer study, the daily treatment with CO 
donor throughout 9 days period, accelerated ulcer healing and upregulated mRNA expression for CTH 
and CBS increasing H2S production at the gastric mucosa of ulcer margin [53]. These observations 
strongly suggest that the effect of CO on CBS and possible activation of compensative mechanisms 
regulating H2S biosynthesis could be time-dependent.
3.2.2. Effects of H2S on CO Biosynthesis Pathway
As mentioned above, the endogenous synthesis of CO depends upon the activity of HMOX-1 
and HMOX-2. As reported previously, H2S can affect the expression of HMOX-1 and endogenous CO 
content indirectly, by modulation of Keap1-Nrf2 pathway [58] (Figure 3). For instance, the pretreatment 
with H2S-releasing derivative of naproxen, ATB-346 increased the expression of Nrf-2 and HMOX-1 
proteins in gastric mucosa compromised by acute stress [32].
Figure 3. Nuclear factor erythroid2-related factor 2 (Nrf-2) mediated modulation of carbon monoxide 
(CO) production by hydrogen sulfide (H2S). Abbreviations: Keapl: Kelch-like ECH-associated protein 
1; ARE: antioxidant response element
As reported by our group previously, daily treatment with H2S-releasing NaHS accelerated gastric 
ulcer healing and decreased mRNA expression of HMOX-1 at ulcer margin supporting the notion that 
this beneficial effect of H2S donor is mediated by anti-inflammatory activity of this gaseous molecule [53]. 
However, pharmacological inhibition of HMOXs by administration of zinc protoporphyrin IX (ZnPP) 
reversed gastroprotective, ulcer healing and vasodilatory effects of H2S donor [53,54]. Interestingly, 
beneficial outcomes of CORM-2 administration in gastric mucosa and gastric microcirculation were 
still observed despite the H2S biosynthesis pathway has been pharmacologically inhibited [43].
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Taken together, these results suggest that, at least within gastric mucosa, H2S activity including 
modulation of gastric microcirculation is dependent on endogenous CO biosynthesis while beneficial 
effects of CO are independent on the activity of endogenous H2S biosynthesis pathway.
4. Conclusions, Possible Implementation into Therapy of GI Disorders and Future Perspectives
CO and H2S donors were shown to exert preventive and therapeutic effects in various digestive 
system disorders and pathologies, such as drugs-induced gastrotoxicity, ulcer healing or prevention 
and treatment of colitis (Figure 4). It has been reported that these gaseous molecules have similar 
molecular targets and could influence each other (Table 1). Nevertheless, the emerging cross-talk and 
interactions between these two molecules remain to be studied. Especially, possible effects of both 
gaseous molecules and novel class of drugs releasing H2S and CO in the therapy of the short-term 
and long-term esophageal pathologies such as GERD, BE or EAC should be further determined. 
Additionally, influence of CO and H2S on the H. pylori infection consequences requires further 
investigations. Lastly, but not limited to, precise mechanisms and effects of CO and H2S on the 
methylation process and regulation of mitochondrial activity, especially in the context of upper GI 
pathologies could significantly expand the current knowledge related to the possible molecular targets 
of these gaseous transmitters and pharmacological agents releasing these gaseous molecules.
Figure 4. Schematic overview of beneficial actions of hydrogen sulfide (H2 S) or carbon monoxide (CO) 
releasing pharmacological tools in physiology and pathophysiology of digestive system pathologies.
Even though the experimental evidence on protective efficacy of CO-donating agents are promising, 
clinical implementation of these compounds into therapy in humans might be questionable since 
many CO-releasing pharmacological tools contain heavy metals in their structure [85]. However, 
novel CO-releasing prodrugs were developed recently and further studies will hopefully reveal their 
clinical potential [86]. It is worth to highlight, that H2S-releasing derivative of naproxen, ATB-346 
with its reduced gastrotoxicity passed successfully the Phase 2 of clinical trial [24]. Taken together, 
there are still many missing aspects to be answered and extensively investigated in the context of CO 
and H2S-related physiology and pharmacology of GI digestive system.
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Table 1. Summary of exemplary beneficial effects of H 2 S and CO.
H2S CO
V h  g  H
Reference 0^ Reference
Beneficial effects of H2S and C O
decreased serum level of TNF-a and IL-1p and expression 
of mRNA in gastric mucosa [5,15]
inhibited production of TNF-a, IL-1p in LPS-stimulated 
macrophages in vivo and in vitro [44]
reduced mRNA and protein expression of HIF-1a in 
gastric mucosa [5,15]
increased IL-10 expression in macrophages via activation
p38MAPK
[87]
Anti-inflammatory supressed NF-k B pathway in gastric mucosa [21] decreased ERK1/2 kinase activity in T cells [88]
induced activation of AnxA1 pathway [21]
re reduced mRNA and protein expression of HIF-1a in 
gastric mucosa and supressed NF-k B pathway in gastric 
mucosa
[15]
involved in regulation of Th1, Th2, and Th17 lymphocyte 
differentiation, decrease of IL-17A content [50]
Anti-oxidative
caused Nrf-2 /HMOX-1pathway upregulation [11,18] inhibited the lipid peroxidation [2]
decreased level of MDA and increased production of 
glutathione (GSH)
[7,56] decreased level of MDA and modulated SOD activity [56,89]
Vasodilatation
increased gastric microcirculation via sGC on endogenous 
NO and CO biosynthesis-dependent manner
[53,54,56]
Increased gastric microcirculation via sGC with contribution 
of NO biosynthesis pathway and independently on 
endogenous H2S activity
[40,42,43,54,56]
dependent on activation of Katp channels [90] dependent on activation of Katp channels [91]
HCO3 - secretion in duodenum increased [64] increased [62,64]
Impact on gut microbiota caused the reconstitution of microbiota biofilm dysbiosis [69,72]
found to be involved in CO/HMOX-1 pathway in cross-talk 
between the microbiota and the mucosal immune 
compartment
[49]
Cross-talk between H2S and C O
D irection M echanism  of action Possible b iological effect References
C O ^  i  H2 S CO can bind to CBS and inhibits its activity
switch of transsulfuration pathway into the remethylation p athw ays methylation 
of proteins^ epigenetic changes [76,77]
H 2 S ^  t c o H2S activates Nrf-2 which and modulates of HMOX-1 
expression and CO production
modulation of oxidative homeostasis and Nrf-2-dependent molecular pathways [18]
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